VG2025
Aliases
V
2 products
1 abstract
4 targets
Target
IL-12Target
IL-15Target
IL-15RαTarget
CEACAM5Abstract
The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Banner MD Anderson Cancer Center, Gilbert, AZ, Virogin Biotech, Jonesville, FL, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Virogin Biotech (Shanghai) Ltd, Shanghai, China,
Product
VG2025Product
RT + V followed by TMZ + V